Jan 21 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:
KEROS THERAPEUTICS ANNOUNCES EFFECTIVENESS OF GLOBAL LICENSE AGREEMENT WITH TAKEDA TO ADVANCE ELRITERCEPT
KEROS THERAPEUTICS INC - TAKEDA TO MAKE $200 MILLION UPFRONT PAYMENT TO CO IN CONNECTION WITH EFFECTIVENESS OF AGREEMENT
Source text: ID:nGNX9LF9Dy
Further company coverage: 4502.T
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.